Title |
Cannabinoid‐1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability
|
---|---|
Published in |
Addiction Biology, September 2011
|
DOI | 10.1111/j.1369-1600.2011.00369.x |
Pubmed ID | |
Authors |
Cleo L. Crunelle, Elsmarieke van de Giessen, Sybille Schulz, Louk J. M. J. Vanderschuren, Kora de Bruin, Wim van den Brink, Jan Booij |
Abstract |
The cannabinoid 1 receptor antagonist rimonabant (SR141716) alters rewarding properties and intake of food and drugs. Additionally, striatal dopamine D2 receptor (DRD2) availability has been implicated in reward function. This study shows that chronic treatment of rats with rimonabant (1.0 and 3.0 mg/kg/day) dose-dependently increased DRD2 availability in the dorsal striatum (14 and 23%) compared with vehicle. High-dose rimonabant also increased DRD2 availability in the ventral striatum (12%) and reduced weight gain. Thus, up-regulation of striatal DRD2 by chronic rimonabant administration may be an underlying mechanism of action and confirms the interactions of the endocannabinoid and dopaminergic systems. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 31 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 9 | 29% |
Researcher | 6 | 19% |
Other | 3 | 10% |
Student > Master | 3 | 10% |
Student > Bachelor | 2 | 6% |
Other | 5 | 16% |
Unknown | 3 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 6 | 19% |
Neuroscience | 6 | 19% |
Agricultural and Biological Sciences | 5 | 16% |
Psychology | 4 | 13% |
Biochemistry, Genetics and Molecular Biology | 2 | 6% |
Other | 1 | 3% |
Unknown | 7 | 23% |